Recently, the National Medical Insurance Administration stated in reply to a proposal from members of the Chinese People's Political Consultative Conference that in recent years, the drugs included in the medical insurance catalog are mainly new drugs approved within 5 years. In the past two years, 155,000 designated retail pharmacies have been added in my country to supply negotiated drugs, which greatly solves the problem. This has solved the bottleneck problem of “can’t get into hospitals” for medicines.
According to the National Medical Insurance Administration, in recent years, my country has accelerated the pace of medical insurance negotiations. The waiting time from the launch of new drugs to the inclusion in the medical insurance catalog has been shortened from an average of 5 years to less than 2 years. Some new drugs were included in the medical insurance catalog only half a year after they were launched.
The drugs included in the medical insurance catalog are mainly new drugs approved within 5 years.
In addition, my country has also established and improved the "dual-channel" supply guarantee mechanism for negotiated drugs, supplying negotiated drugs to patients through two channels: hospitals and retail pharmacies, and implementing the same reimbursement policy. Within 2 years, 155,000 designated retail pharmacies have been added to supply negotiated drugs. .
In principle, the negotiated drug agreement is valid for 2 years.
Considering that newly launched drugs have a short time to enter the market and sales changes are unpredictable, the National Medical Insurance Administration inspects the use of drug funds every two years and adjusts payment standards based on the actual sales of drugs.
According to the current "Rules for Negotiating Drug Contract Renewals", exclusive drugs that have not adjusted their payment standards and payment scope for two consecutive agreement periods can be included in the regular drug catalog management. This will help stabilize corporate expectations, reduce pressure on price reductions in the later period, and reduce contract renewal failures. possibility.
In previous adjustments to the medical insurance drug catalog, the National Medical Insurance Administration has always determined price levels based on the benefits that drugs bring to patients, significantly improving the cost-effectiveness of newly admitted drugs.
As the negotiation work progresses, the bureau has established a set of indicator systems that are in line with my country's reality, achieving a leap from "subjective to objective" and "from qualitative to quantitative" in drug review, and measuring innovation more accurately and scientifically.
The National Medical Insurance Administration stated that overall, the adjustment of my country's medical insurance drug catalog in the past five years has better served the majority of insured persons. Patients have used innovative drugs with better efficacy at more reasonable prices, which has also promoted the development of my country's pharmaceutical industry. We have established a high-quality development path that emphasizes innovation and strong R&D.
(The Paper reporter Zhang Yilin)